Acquired immunodeficiency syndrome a disease with high mortality rates is caused by the well-known human immunodeficiency virus. The disease is characterized by several opportunistic infections owing to the decreased CD4 lymphocyte counts. Oral manifestations of human immunodeficiency virus are vital as they are one of the early manifestations of the disease. Also, they serve as prognostic markers as they correlate with the CD4 lymphocyte counts of the affected individuals. Human immunodeficiency virus is not only common in the adult population but also can affect pediatric patients through vertical transmission. The initial therapeutic strategy for the management of the virus was only the prevention of opportunistic infections. Later in the mid-1990s, antiretroviral therapy was introduced but there was no significant improvement in prognosis. After the advent of combination therapy or the use of three antiretroviral drugs also known as highly active antiretroviral therapy, there has been a marked reduction in human immunodeficiency virus-associated mortality rates. The highly active antiretroviral therapy has several effects on the oral manifestations of the human immunodeficiency virus. The present paper aims to review the oral pigmented lesions associated with human immunodeficiency virus with an emphasis on the effect of highly active antiretroviral therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.disamonth.2021.101167 | DOI Listing |
JMIR Res Protoc
January 2025
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Background: Although existing disease preparedness and response frameworks provide guidance about strengthening emergency response capacity, little attention is paid to health service continuity during emergency responses. During the 2014 Ebola outbreak, there were 11,325 reported deaths due to the Ebola virus and yet disruption in access to care caused more than 10,000 additional deaths due to measles, HIV/AIDS, tuberculosis, and malaria. Low- and middle-income countries account for the largest disease burden due to HIV, tuberculosis, and malaria and yet previous responses to health emergencies showed that HIV, tuberculosis, and malaria service delivery can be significantly disrupted.
View Article and Find Full Text PDFRev Bras Enferm
January 2025
Universidade Franciscana. Santa Maria, Rio Grande do Sul, Brazil.
Objectives: to compare the sociodemographic and clinical severity indicators of hospitalized people with HIV in relation to clinical outcomes and urgent hospital admission.
Methods: a retrospective cohort study was conducted with 102 medical records of HIV-infected individuals hospitalized in a hospital in southern Brazil. In addition to descriptive analysis, Fisher's exact test, Pearson's Chi-square, and logistic regression were used.
Rev Bras Enferm
January 2025
Universidade de Pernambuco. Recife, Pernambuco, Brazil.
Objectives: to verify the construct validation of an instrument for evaluating care for people living with HIV in Primary Health Care.
Methods: methodological study carried out in 2021 with 260 health professionals in Recife, PE. Validation based on the internal structure was carried out at this stage using exploratory and confirmatory factor analysis, and validity based on item response theory.
Epidemiol Serv Saude
January 2025
Universidade Federal Fluminense, Departamento de Enfermagem, Rio das Ostras, RJ, Brasil.
Objective: To analyze the relationship between childhood abuse and self-harm in a group of transvestites and transgender women from the state of Rio de Janeiro.
Methods: This was a cross-sectional study conducted with 139 participants selected through convenience sampling between 2019 and 2020. A structured questionnaire was used for data collection.
Epidemiol Serv Saude
January 2025
Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Brasília, DF, Brasil.
Objectives: To analyze access to pre-exposure prophylaxis (PrEP) for HIV in Brazil, comparing transgender and cisgender populations.
Methods: This was a descriptive study using data from the Medication Logistics Control System (Sistema de Controle Logístico de Medicamentos - SICLOM), related to the monitoring of PrEP between January 2018 and December 2023.
Results: During the period analyzed, 149,022 people initiated PrEP, of whom 139,423 (94%) were cisgender and 9,599 (6%) were transgender.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!